The US Food and Drug Administration has issued its first-ever approval of a cellular immunotherapy. The product, Provenge (sipuleucel-T), is a therapeutic vaccine developed by Dendreon Corp of Seattle, Washington. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy
